<?xml version="1.0" encoding="UTF-8"?>
<p>A more recent study conducted by McLean
 <xref rid="irv12664-bib-0054" ref-type="ref">54</xref> reported a similar effectiveness provided by a Q‐LAIV and IIV against a new antigenic A(H3N2) variant, whereas a considerable higher protection was provided by Q‐LAIV compared to IIV toward a drifted influenza B strain.
</p>
